• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    2/10/22 8:28:05 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    SC 13G/A 1 tv01576-omnicellinc.htm SCHEDULE 13G/A omnicellinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  Omnicell Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  68213N109

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  68213N109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    83,188

    7.  SOLE DISPOSITIVE POWER

    4,619,447

    8.  SHARED DISPOSITIVE POWER

    121,046

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,740,493

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.79%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Omnicell Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    590 East Middlefield Road
    Mountain View, CA 94043-1337

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    68213N109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    9/26/2023$56.00 → $39.00Underweight
    Wells Fargo
    More analyst ratings

    $OMCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

      The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

      9/25/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

      FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

      4/22/24 4:05:00 PM ET
      $CLOV
      $OMCL
      Medical Specialities
      Health Care
      Computer Manufacturing
      Technology
    • Omnicell Elects Eileen Voynick to Board of Directors

      Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

      1/11/24 4:00:00 PM ET
      $MDRX
      $OMCL
      $CDK
      EDP Services
      Technology
      Computer Manufacturing
      Retail: Computer Software & Peripheral Equipment

    $OMCL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Omnicell Inc.

      10-Q - OMNICELL, INC. (0000926326) (Filer)

      5/7/25 4:03:30 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      5/6/25 6:34:17 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form DEF 14A filed by Omnicell Inc.

      DEF 14A - OMNICELL, INC. (0000926326) (Filer)

      4/3/25 5:09:39 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EVP, Chief Operating Officer Njoku Nnamdi was granted 37,409 shares, increasing direct ownership by 70% to 90,929 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:14:39 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J was granted 22,445 shares and covered exercise/tax liability with 71 shares, increasing direct ownership by 23% to 120,281 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:12:23 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BofA Securities with a new price target

      BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

      10/31/24 7:49:39 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Barclays with a new price target

      Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

      8/2/24 7:36:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Barclays initiated coverage on Omnicell with a new price target

      Barclays initiated coverage of Omnicell with a rating of Underweight and set a new price target of $33.00

      1/3/24 8:05:18 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

      Medical device, pharmaceutical, and life sciences expert tapped to lead Company's technology strategy and global engineering organization Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250324514095/en/Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, on March 31, 2025. Dr. Genova will lead Omnicell's technology str

      3/24/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Financials

    Live finance-specific insights

    See more
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

      Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

      2/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      12/11/23 9:36:42 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      9/11/23 1:33:44 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      2/9/23 11:27:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology